secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001104659-23-120365
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences grants RSUs to executives post-IPO; CEO Happel receives 624,910 units
--------------------------------------------------------------------------------

- Board approved RSU grants: CEO David Happel (624,910), Eduardo Martins (89,570), George Kemble (150,750).
- RSUs vest 25% on first anniversary of IPO closing, remainder over three years, subject to continued service.
- Compensation Committee engaged Compensia to align executive compensation with public-company peers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923120365/0001104659-23-120365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923120365/tm2331242d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer